Neurocrine Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NEUROCRINE
NEUROCRINE has four approved drugs.
There are twenty-seven US patents protecting NEUROCRINE drugs.
Summary for Neurocrine
| US Patents: | 27 |
| Tradenames: | 3 |
| Ingredients: | 2 |
| NDAs: | 4 |
| Patent Litigation for Neurocrine: | See patent lawsuits for Neurocrine |
Drugs and US Patents for Neurocrine
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | INGREZZA SPRINKLE | valbenazine tosylate | CAPSULE;ORAL | 218390-002 | Apr 30, 2024 | RX | Yes | No | 11,439,629 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Neurocrine | INGREZZA SPRINKLE | valbenazine tosylate | CAPSULE;ORAL | 218390-002 | Apr 30, 2024 | RX | Yes | No | 8,357,697 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Neurocrine | CRENESSITY | crinecerfont | SOLUTION;ORAL | 218820-001 | Dec 13, 2024 | RX | Yes | Yes | 11,311,544 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Neurocrine Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 3051834 | ⤷ Start Trial |
| South Korea | 20210044817 | ⤷ Start Trial |
| Mexico | 2009004910 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
